Home » Stocks » IDYA

IDEAYA Biosciences, Inc. (IDYA)

Stock Price: $23.93 USD 1.21 (5.33%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
Market Cap 922.30M
Revenue (ttm) 26.79M
Net Income (ttm) -31.47M
Shares Out 31.76M
EPS (ttm) -1.14
PE Ratio n/a
Forward PE 4.65
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $23.93
Previous Close $22.72
Change ($) 1.21
Change (%) 5.33%
Day's Open 22.83
Day's Range 22.40 - 24.20
Day's Volume 89,940
52-Week Range 10.90 - 26.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOUTH SAN FRANCISCO, Calif., July 12, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 5,333,333 shares of its common stock ...

2 weeks ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., July 7, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of 4,637,681 shares of its common stock at...

3 weeks ago - PRNewsWire

Ideaya Biosciences Inc (NASDAQ: IDYA) has offered up to $80 million shares in an underwritten public offering.  Underwriters have an option to purchase up to $12 million of shares.

3 weeks ago - Benzinga

SOUTH SAN FRANCISCO, Calif., July 6, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $80 million of shares of its common stock in an u...

3 weeks ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., June 28, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and develo...

1 month ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., May 24, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develo...

2 months ago - PRNewsWire

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0.00% and -27.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., May 10, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and develop...

2 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., May 10, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develo...

2 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., May 6, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develop...

2 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., April 19, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...

3 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., April 16, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...

3 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., April 15, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...

3 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., April 15, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...

3 months ago - PRNewsWire

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 0.00% and -2.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., March 23, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...

4 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., March 23, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and devel...

4 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., March 11, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and deve...

4 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., March 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and devel...

4 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 /PRNewswire/ --IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develo...

5 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and devel...

5 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 8, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and develo...

5 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted t...

5 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted t...

6 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted th...

6 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 4, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted th...

6 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 14, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted ...

7 months ago - PRNewsWire

IDEAYA Biosciences (IDYA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted ...

8 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted th...

8 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted ...

9 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted...

10 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.

10 months ago - PRNewsWire

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -126.34% and -100.00%, respectively, for the quarter ended June 2020.

11 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.

11 months ago - PRNewsWire

IDEAYA Biosciences (IDYA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

11 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Aug. 4, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.

11 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., July 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc.

1 year ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., July 14, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted ...

1 year ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., July 9, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted th...

1 year ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., June 30, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted t...

1 year ago - PRNewsWire

A high-profile partnership and a promising pipeline of oncology-focused treatments suggest favorable reward-versus-risk in IDYA stock. The post Target Breakthrough Science and Medicine with Ideaya Biosc...

1 year ago - InvestorPlace

Here's what pushed up shares of the highest-flying healthcare stocks.

Other stocks mentioned: CLDX, QDEL
1 year ago - The Motley Fool

The development-stage drug developer is selling common stock to raise cash. It's a wise move.

1 year ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., June 17, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock ...

1 year ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., June 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $60 million of shares of its common stock in an ...

1 year ago - PRNewsWire

IDEAYA Biosciences (NASDAQ: IDYA) shares are trading higher on Tuesday, after the company, along with GSK, announced a partnership in Synthetic Lethality.

1 year ago - Benzinga

SOUTH SAN FRANCISCO, Calif. and LONDON, June 16, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and GlaxoSmithKline plc (GSK) announce a strategic partnership in Synthetic Lethality, an em...

1 year ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., June 11, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted...

1 year ago - PRNewsWire

IDEAYA (IDYA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

About IDYA

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients wit... [Read more...]

Industry
Biotechnology
IPO Date
May 23, 2019
CEO
Yujiro Hata
Employees
69
Stock Exchange
NASDAQ
Ticker Symbol
IDYA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for IDYA stock is "Strong Buy." The 12-month stock price forecast is 31.56, which is an increase of 31.88% from the latest price.

Price Target
$31.56
(31.88% upside)
Analyst Consensus: Strong Buy